Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective

Mauricio P. Pinto, Matías Muñoz Medel, Diego Carrillo, Ignacio N. Retamal, M. Loreto Bravo, Yasna Valenzuela, Bruno Nervi, César Sánchez, Héctor Galindo, Carolina Ibañez, José Peña, Carlos Balmaceda, Jorge Madrid, Juan Briones, Javiera Torres, Flavia Nilo, Francisco J. Guarda, Juan Carlos Quintana, Pilar Orellana, Sebastián MondacaFrancisco Acevedo, Daniel Vicentini, Miguel Cordova-Delgado, Gareth I. Owen, Marcelo Garrido*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Neuroendocrine tumors (NETs) are relatively rare and highly heterogeneous neoplasms. Despite this, recent studies from North America and Central Europe have suggested an increase in incidence. In Latin America, NET data are scarce and scattered with only a few studies reporting registries. Our goal was to establish a NET registry in Chile. Here, we report the establishment and our first 166 NET patients. We observed a slight preponderance of males, a median age at diagnosis of 53 years and a median overall survival of 110 months. As anticipated, most tumors were gastroenteropancreatic (GEP). Survival analyses demonstrated that non-GEP or stage IV tumors presented significantly lower overall survival (OS). Similarly, patients with surgery classified as R0 had better OS compared to R1, R2, or no surgery. Furthermore, patients with elevated chromogranin A (CgA) or high Ki67 showed a trend to poorer OS; however, these differences did not reach statistical significance (log-rank test p = 0.07). To the best of our knowledge, this is the first report of a NET registry in Chile. Median OS in our registry (110 months) is in line with other registries from Argentina and Spain. Other variables including age at diagnosis and gender were similar to previous studies; however, our data indicate a high proportion of small-bowel NETs compared to other cohorts, reflecting the need for NET regional registries. Indeed, these registries may explain regional discrepancies in incidence and distribution, adding to our knowledge on this seemingly rare, highly heterogeneous disease.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalHormones and Cancer
Issue number1
StatePublished - 1 Feb 2019
Externally publishedYes

Bibliographical note

Funding Information:
A team of specialists that included medical oncologists, endocrinologists, gastroenterologists, nurses, and molecular biologists generated this registry. The registry was funded by Novartis, Chile. Novartis had no access to patient raw data or any participation in the establishment of the database, data acquisition, or analysis. This study was designed as an observational, multicenter, prospective, and retrospective registry, and approved by the institutional review board and ethics committee in all participating institutions, in accordance with the Declaration of Helsinki, Good Clinical Practices, and Chilean regulations. Participating institutions with ethics approval included the following: Hospital Base de Valdivia, Hospital de Punta Arenas, Hospital Dr. Sotero del Rio, Hospital Base de Osorno, Hospital Regional de Concepcion, and Hospital Clinico de la Universidad de Chile. Written informed consent was obtained from all participating patients.

Publisher Copyright:
© 2018, The Author(s).


  • Cancer registry
  • Chromogranin A
  • Neuroendocrine tumors
  • Overall survival


Dive into the research topics of 'Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective'. Together they form a unique fingerprint.

Cite this